Vera Therapeutics Inc (VERA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $34.00 (-0.79%), Market cap $2.81B, 52-week low–high $18.87 ~ $55.67.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-in
Financial statements, price targets, institutional (13F) holdings and related news for Vera Therapeutics Inc are updated in real time on BlackAll Trade.
Vera Therapeutics Inc trades at $34.00 (-0.79%). Real-time quotes and charts are available on BlackAll Trade.
Vera Therapeutics Inc has a market cap of about $2.81B.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company off